Latest Pharmaceutical Distribution News

Page 1 of 2
Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.
Ada Torres
Ada Torres
17 Nov 2025
EBOS Group Limited has updated its Dividend Reinvestment Plan rules, offering shareholders new ways to reinvest dividends into additional shares. The changes, effective immediately, provide greater flexibility and maintain board discretion over share issuance terms.
Ada Torres
Ada Torres
13 Nov 2025
EBOS Group Limited has updated its final dividend details for the six months ending June 2025, confirming a fully franked ordinary dividend and specifying the Dividend Reinvestment Plan strike price.
Ada Torres
Ada Torres
17 Sept 2025
BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.
Ada Torres
Ada Torres
28 Aug 2025
BTC Health reports a strong FY25 with a $4 million statutory profit, boosted by a $5 million contract and strategic acquisition. The company eyes further growth in FY26 with new product launches and expanded market reach.
Ada Torres
Ada Torres
28 Aug 2025
EBOS Group Limited reported a 7% drop in revenue and a 21% fall in net profit for FY2025, reflecting ongoing cost pressures and restructuring impacts. The company declared a final dividend, signaling cautious optimism despite the earnings setback.
Ada Torres
Ada Torres
27 Aug 2025
EBOS Group Limited has reported a 7% decline in revenue and a 21% drop in net profit for FY2025, yet it maintains its final dividend at 61.5 NZ cents per share. The results reflect ongoing cost pressures and restructuring expenses amid a challenging market environment.
Ada Torres
Ada Torres
27 Aug 2025
Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.
Ada Torres
Ada Torres
19 Aug 2025
Sigma Healthcare has released its standalone annual and sustainability reports for the year ending January 2025, marking the final disclosures before its merger with Chemist Warehouse Group in February 2025.
Ada Torres
Ada Torres
15 May 2025
Sigma Healthcare’s recent merger with Chemist Warehouse Group is delivering strong earnings growth, with Normalised EBIT rising 36% in the first half of FY25. Transaction costs remain significant but the combined group’s outlook appears robust.
Ada Torres
Ada Torres
6 May 2025
Sigma Healthcare has raised its FY25 normalised EBIT guidance to $64-$70 million, driven by robust operational performance and the successful rollout of a key supply contract with Chemist Warehouse.
Ada Torres
Ada Torres
7 Feb 2025
Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.
Ada Torres
Ada Torres
31 Jan 2025